Even in breast cancer, wherein HER2 amplification is historically correlated with overexpressions of mRNA and protein [98,99], Luoh et al. have shown that a subset of patients with HER2 gene amplification did not overexpress the HER2 protein, which may affect the response to HER2-targeted therapies [100]. Here, ERBB2 is linked to breast carcinoma.